Presentation is loading. Please wait.

Presentation is loading. Please wait.

Nat. Rev. Neurol. doi: /nrneurol

Published byBridget Ball Modified over 6 years ago

Similar presentations

Presentation on theme: "Nat. Rev. Neurol. doi: /nrneurol"— Presentation transcript:

1 Nat. Rev. Neurol. doi:10.1038/nrneurol.2017.171
Figure 1 Trends over time in phase III clinical trials in relapsing and progressive MS Figure 1 | Trends over time in phase III clinical trials in relapsing and progressive MS. a | The number of phase III clinical trials has greatly increased in the past 5 years, especially in relapsing multiple sclerosis (MS). Clear increases over the past 5–10 years are also evident in b | the number of end points per trial and c | the number of participants per trial. d | By contrast, trial duration has remained broadly unchanged, with most trials having a duration of 2 years or 3 years. CIS, clinically isolated syndrome; PPMS, primary progressive MS; SPMS, secondary progressive MS. Tur, C. et al. (2018) Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting Nat. Rev. Neurol. doi: /nrneurol

Download ppt "Nat. Rev. Neurol. doi: /nrneurol"

Similar presentations

Study Design 121 Relapsing-remitting MS patients randomized to –Stress Management Therapy MS active treatment* 16 individual sessions conducted over 24.

Study Design 121 Relapsing-remitting MS patients randomized to –Stress Management Therapy MS active treatment* 16 individual sessions conducted over 24.
Defining the Clinical Course of Multiple Sclerosis.

Defining the Clinical Course of Multiple Sclerosis.
Journal Insights Into: Oral Therapy for MS-Related Walking Impairment Supplemental Slides.

Journal Insights Into: Oral Therapy for MS-Related Walking Impairment Supplemental Slides.
Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.

Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.
Personal Experiences of Progressive Multiple Sclerosis (MS)

Personal Experiences of Progressive Multiple Sclerosis (MS)
Four Known Types of MS Clinically isolated syndrome (CIS)

Four Known Types of MS Clinically isolated syndrome (CIS)
Copyright © 2014 American Medical Association. All rights reserved.

Copyright © 2014 American Medical Association. All rights reserved.
Nat. Rev. Neurol. doi:10/1038/nrneurol

Nat. Rev. Neurol. doi:10/1038/nrneurol
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Figure 4 Progression-free survival, according to treatment group

Figure 4 Progression-free survival, according to treatment group
Figure 3 Life expectancy at birth in all countries included

Figure 3 Life expectancy at birth in all countries included
Figure 1 Perivenous distribution of multiple sclerosis lesions

Figure 1 Perivenous distribution of multiple sclerosis lesions
Figure 2 The US Centers for Disease Control and

Figure 2 The US Centers for Disease Control and
Figure 4 Time course of the development of physiological changes

Figure 4 Time course of the development of physiological changes
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Figure 1 Hypothetical staging model of sporadic Alzheimer disease (AD)

Figure 1 Hypothetical staging model of sporadic Alzheimer disease (AD)
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Figure 2 Overview of risk factors for Parkinson disease dementia

Figure 2 Overview of risk factors for Parkinson disease dementia
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Similar presentations

Ads by Google